Treatment of severe Hemophilia A (SHA) with FVIII concentrates is complicated by development of neutralizing inhibitors in about 30% during the first 50 exposure days (EDs). Despite extensive research,...
Lire la suite

The development of neutralising antibodies (inhibitors) against FIX is the most serious complication of treatment in severe haemophilia B (SHB), and given the overall rarity of inhibitor formation (5%-10%),...
Lire la suite

Repeated joint bleeds cause hemophilic arthropathy, which can develop despite regular prophylaxis with clotting factors. Therefore, recognizing ongoing or subclinical bleeds is an important element of...
Lire la suite

Advances in hemophilia treatment, including extended half-life factor concentrates, non-replacement therapies, and gene therapy, have substantially reduced bleeding frequency and improved life expectancy. However, persistent musculoskeletal damage, subclinical bleeding, and residual arthropathy remain important clinical challenges despite improved hematologic control. We aimed to analyze recent therapeutic advances in hemophilia, examine persistent...
Lire la suite